This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MFSD8 | |
|---|---|
| Name | MFSD8 |
| Uniprot | Q96Q42 |
| Chromosomal location | 4q28.2 |
| Omim | 610951 |
| Protein length | ~357 aa |
MFSD8 MFSD8 is a membrane protein encoded by a nuclear gene implicated in lysosomal function and neurodegenerative disease. It is linked to neuronal ceroid lipofuscinosis and interacts with pathways studied across cell biology, neuroscience, genetics, and pharmacology. Research on MFSD8 connects to clinical neurology, pediatric neurology, and rare disease networks.
MFSD8 participates in lysosomal transport and homeostasis, interacting with pathways characterized in Lysosome, Autophagy, Endocytosis, Protein trafficking, V-ATPase complex and studied alongside factors such as LAMP1, LAMP2, Cathepsin D, CLN3, CLN5 and CLN7. Studies reference models from Homo sapiens, Mus musculus, Rattus norvegicus, Drosophila melanogaster and Caenorhabditis elegans to define roles in neuronal maintenance, synaptic function and lysosomal pH regulation similar to mechanisms described for Niemann–Pick disease and Pompe disease. Functional assays often involve methodologies developed by groups at institutions including National Institutes of Health, Wellcome Trust, Max Planck Society, Harvard University and Stanford University.
MFSD8 is located on chromosome 4q28.2 and was mapped in cohorts analyzed by consortia such as 1000 Genomes Project, Exome Aggregation Consortium, Genome Aggregation Database and clinical projects at ClinVar, OMIM and DECIPHER. Population genetics studies reference datasets from UK Biobank, gnomAD, HapMap and epidemiological work from Centers for Disease Control and Prevention and World Health Organization. Variants in MFSD8 were identified through sequencing pipelines developed at Broad Institute, Illumina, Baylor College of Medicine, Sanger Institute and clinical genetics services at Mayo Clinic, Johns Hopkins Hospital and Great Ormond Street Hospital.
The MFSD8 protein is predicted to contain multiple transmembrane helices and belongs to the major facilitator superfamily; structural inference uses approaches from Cryo-electron microscopy, X-ray crystallography, AlphaFold, Rosetta and homology modeling with templates like GlpT and other transporters studied at European Molecular Biology Laboratory and Institute Pasteur. Localization studies employ markers such as Rab7, Rab5, LAMP2 and imaging platforms from Zeiss, Leica Microsystems, Nikon and techniques developed by groups at MIT and Caltech.
Biallelic pathogenic variants in MFSD8 cause a form of neuronal ceroid lipofuscinosis (CLN7), described in clinical literature from American Academy of Neurology, European Academy of Neurology and case series reported by centers including Boston Children's Hospital, Great Ormond Street Hospital, Texas Children's Hospital and Children's Hospital of Philadelphia. The phenotype overlaps with syndromes catalogued by Orphanet, NIH Rare Diseases Program and registries maintained by European Reference Network. Presentations include developmental regression, seizures, visual loss, and motor decline reported in publications from New England Journal of Medicine, Brain, Annals of Neurology and Neurology.
Pathogenic mechanisms implicate impaired lysosomal substrate transport, accumulation of autofluorescent storage material, disrupted autophagic flux, altered synaptic vesicle recycling and neuronal vulnerability similar to mechanisms studied in Alzheimer's disease, Parkinson's disease, Huntington's disease, Frontotemporal dementia and Amyotrophic lateral sclerosis. Molecular studies cite signaling networks involving mTOR, TFEB, Beclin 1, Atg5 and lipid handling pathways characterized by NPC1 and SMPD1. Proteomic and lipidomic analyses have been carried out using platforms from Thermo Fisher Scientific and laboratories at European Molecular Biology Laboratory and Scripps Research Institute.
Knockout and knock-in models for MFSD8 have been generated in Mus musculus and studied at centers including Jackson Laboratory, European Mouse Mutant Archive and research groups at University of Pennsylvania and University College London. Studies in Drosophila melanogaster and Caenorhabditis elegans provide conserved insight comparable to models of CLN3 and CLN5, while in vitro systems use human induced pluripotent stem cells differentiated in labs at Stanford University, Columbia University and University of Cambridge. Preclinical work utilizes behavioral assays, neuroimaging at facilities like UCL Queen Square Institute of Neurology and electrophysiology methods developed at Max Planck Institute for Brain Research.
Therapeutic strategies under investigation include gene replacement, antisense oligonucleotides, small-molecule modifiers, enzyme replacement concepts and substrate reduction strategies, informed by trials run by organizations such as National Institutes of Health, European Medicines Agency, Food and Drug Administration and biotech firms including Biogen, Genentech, Novartis, Sarepta Therapeutics and Bluebird Bio. Research priorities align with initiatives at Global Alliance for Genomics and Health, Rare Diseases Clinical Research Network and patient advocacy groups like EveryLife Foundation for Rare Diseases and NCL Foundation focusing on biomarkers, natural history and outcome measures analogous to efforts in Spinal Muscular Atrophy and Duchenne muscular dystrophy. Ongoing work leverages CRISPR technologies from Broad Institute and delivery platforms informed by studies at Massachusetts General Hospital and Children's Hospital Boston.
Category:Human proteins